Company intelligence / Profile preview

Primocure Pharma, Inc.

New York City, New York, United States

Ownership: Private
Development stage: Other

Overview

Primocure Pharma, Inc. is a private pharmaceutical company based in New York focused on developing small molecule therapeutics for oncology indications. Its lead asset, KAT‑101, targets fibrolamellar hepatocellular carcinoma and has reached Phase 2 clinical trials. The company previously received FDA orphan drug designation for an opioid growth factor–based therapy targeting liver and intrahepatic bile duct cancers but does not have any approved products yet.

Therapeutic areas: Oncology
Modalities: Small moleculesPeptide-based therapy
Industry: Biotech

Partnerships

NewG Lab Pharma Co., Ltd. — originator of KAT‑101 licensed to Primocure Pharma.KoDiscovery — referenced as a parent or affiliate involved with orphan drug status filings.NIH grant/funding relationships possible but not detailed publicly.

Beyond the preview

Go deeper on Primocure Pharma, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Primocure Pharma, Inc..